Here, we demonstrated that the c-Myc inhibitor KSI-3716 was cytotoxic to gemcitabine-resistant bladder cancer cells, suggesting that c-Myc inhibitors could be a viable treatment option when MDR is involved. Here, MYC is linked to urinary bladder carcinoma.